[
  {
    "ts": null,
    "headline": "Invesco Charter Fund Q3 2025 Portfolio Positioning And Performance Highlights",
    "summary": "Invesco Charter Fundâs Class A shares at net asset value returned 6.50% for the quarter, underperforming the Russell 1000 Index, which returned 7.99%. Read more here.",
    "url": "https://finnhub.io/api/news?id=c9ba818a755808d50887d61fd30d71310804f851e5abe71bc5504bb699eff1fd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765721580,
      "headline": "Invesco Charter Fund Q3 2025 Portfolio Positioning And Performance Highlights",
      "id": 137786191,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2236769794/image_2236769794.jpg?io=getty-c-w1536",
      "related": "ZBH",
      "source": "SeekingAlpha",
      "summary": "Invesco Charter Fundâs Class A shares at net asset value returned 6.50% for the quarter, underperforming the Russell 1000 Index, which returned 7.99%. Read more here.",
      "url": "https://finnhub.io/api/news?id=c9ba818a755808d50887d61fd30d71310804f851e5abe71bc5504bb699eff1fd"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Zimmer Biomet After Share Price Weakness and Discounted Cash Flow Outlook",
    "summary": "Wondering if Zimmer Biomet Holdings is quietly becoming a value opportunity, or if the recent weakness is a warning sign? Let us walk through what the numbers are really saying about the stock. The share price is down about 2.9% over the last week and still roughly 13.4% lower than a year ago, even after a modest 1.9% gain over the past month. Over a longer horizon, the stock remains well below where it was 3 and 5 years ago. That naturally raises questions about sentiment and potential...",
    "url": "https://finnhub.io/api/news?id=4993e6125a8859826501b799734dec88925845bbe178ceb980ad98a0cee4715e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765696001,
      "headline": "Assessing Zimmer Biomet After Share Price Weakness and Discounted Cash Flow Outlook",
      "id": 137793263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Wondering if Zimmer Biomet Holdings is quietly becoming a value opportunity, or if the recent weakness is a warning sign? Let us walk through what the numbers are really saying about the stock. The share price is down about 2.9% over the last week and still roughly 13.4% lower than a year ago, even after a modest 1.9% gain over the past month. Over a longer horizon, the stock remains well below where it was 3 and 5 years ago. That naturally raises questions about sentiment and potential...",
      "url": "https://finnhub.io/api/news?id=4993e6125a8859826501b799734dec88925845bbe178ceb980ad98a0cee4715e"
    }
  }
]